TABLE 1.

Donor variability in susceptibility to AT-2-inactivated virion-induced T-cell apoptosis and CD4⁺ T-lymphocyte depletion^a

^aPBMC were isolated from 16 random, healthy, HIV-seronegative donors and either mock treated or treated with MHC-positive or MHC-negative microvesicles (10 μg/ml) or AT-2-inactivated MHC-positive HIV-1_{NL4-3/CEMX174/(T1)} or MHC-negative HIV-1_{NL4-3/CEMX174/(T2)} (10 ng of p24 per ml). After 10 days, PBMC were analyzed for Fas-expressing CD4⁺ T-lymphocytes, for absolute numbers of CD4⁺ T-lymphocytes, and for the percentage of apoptotic (annexin V⁺) CD4⁺ T lymphocytes by flow cytometry. Donors were segregated into three groups depending on whether they were matched homozygous for HLA-DRB∗0701, HLA-DRB∗0701 haploidentical, or completely mismatched relative to CEMX174/(T1).